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Tertiary lymphoid organs (TLOs) emerge in tissues in response to non-resolving inflamma-
tion such as chronic infection, graft rejection, and autoimmune disease.We identified artery
TLOs (ATLOs) in the adventitia adjacent to atherosclerotic plaques of aged hyperlipidemic
ApoE−/− mice. ATLOs are structured intoT cell areas harboring conventional dendritic cells
and monocyte-derived DCs; B cell follicles containing follicular dendritic cells within acti-
vated germinal centers; and peripheral niches of plasma cells. ATLOs also show extensive
neoangiogenesis, aberrant lymphangiogenesis, and high endothelial venule (HEV) neogen-
esis. Newly formed conduit networks connect the external lamina of the artery with HEVs
in T cell areas. ATLOs recruit and generate lymphocyte subsets with opposing activities
including activated CD4+ and CD8+ effector T cells, natural and induced CD4+ T regula-
tory (nTregs; iTregs) cells as well as B-1 and B-2 cells at different stages of differentiation.
These data indicate that ATLOs organize dichotomic innate and adaptive immune responses
in atherosclerosis. In this review we discuss the novel concept that dichotomic immune
responses toward atherosclerosis-specific antigens are carried out by ATLOs in the adven-
titia of the arterial wall and that malfunction of the tolerogenic arm of ATLO immunity
triggers transition from silent autoimmune reactivity to clinically overt disease.
Keywords: adaptive immune responses, artery tertiary lymphoid organs, atherosclerosis, autoimmunity,
inflammation, stable plaque, vulnerable plaque
TLOs ARISE IN CHRONIC NON-RESOLVING INFLAMMATION
OF PERIPHERAL TISSUES
The immune system aims at identification and destruction of for-
eign antigens while preserving self (Shlomchik et al., 2001; Cyster,
2003; Drayton et al., 2003, 2006; Gommerman and Browning,
2003; Cupedo et al., 2004; Browning et al., 2005; Aloisi and Pujol-
Borrell, 2006; Browning, 2006; Goodnow, 2007; Carragher et al.,
2008; Shlomchik, 2008, 2009). To achieve this task, both innate and
adaptive immune responses are intrinsically dichotomic in nature:
elimination of antigen is associated with tissue inflammation with
the potential to cause collateral damage leading to organ dysfunc-
tion. However, to protect the host from inflammation-triggered
injury, the immune system employs a series of powerful strategies.
It puts potent cells to work which implement versatile tools to con-
stantly equilibrate the balance between destruction and protection.
As long as this balance is efficiently maintained, organ damage
can be avoided, and resolution of inflammation will be success-
ful (Nathan and Ding, 2010). Generation of inflammatory versus
anti-inflammatory leukocytes is achieved by cytokine-driven dif-
ferentiation pathways creating innate and adaptive immune cell
subsets in bone marrow, spleen, and peripheral tissues where anti-
gens may arise. Mouse models have contributed much to our
current understanding of human chronic inflammatory diseases
but translation of experimental data to human diseases remains a
major challenge (Van De Pavert et al., 2009; Blumberg et al., 2012;
Roep et al., 2012). Innate immune cells are generated in highly
localized tissue microdomains as shown for mouse Ly6C+ and
Ly6C−monocytes, M1- and M2-like tissue macrophages, immune
response-promoting, and tolerogenic dendritic cells (DCs) as well
as B-1a and B-1b cells (Libby, 2002; Alugupalli et al., 2004; Swirski
et al., 2007; Tacke et al., 2007; Koltsova and Ley, 2011; Manthey and
Zernecke, 2011). Likewise, the adaptive immune system generates
antigen-specific T and B effector cells and their equally pow-
erful tolerogenic antigen-specific T and B regulatory cell (Treg;
Breg) counterparts (see below). Innate immune cells eliminate
the antigen within minutes to hours before T and B cell acti-
vation, memory cell generation, clonal expansion, and affinity
maturation are initiated. However, if antigen generation continues
beyond the critical time window of 12–24 h and antigen eradi-
cation through innate immune cells fails, vigorous T and B cell
responses are triggered (Mempel et al., 2004). Even under these
conditions, an equilibrium between effector and tolerogenic lym-
phocyte responses prevents outbreak of clinical disease as shown
by the presence of autoreactive T and B cells in a large percent-
age of the healthy population (Lang et al., 2005; Lopez-Diego and
Weiner, 2008). However, chronic disturbance of this balance leads
to tissue destruction and autoimmune injury (Nathan and Ding,
2010; Kuchroo et al., 2012). How tissue inflammation prompts
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the adaptive immune system to organize T and B cell immune
responses through danger signal-activated antigen-presenting cells
(APCs) is of major interest to understand principles of adaptive
immunity, autoimmunity, and atherosclerosis (Mach et al., 1998;
Ludewig et al., 2000; McLachlan and Rapoport, 2004; Goodnow,
2007; Herlands et al., 2008;Shlomchik, 2008, 2009; Galkina and
Ley, 2009; Packard et al., 2009; Cheong et al., 2010; McInnes and
Schett, 2011; Blumberg et al., 2012; Kuchroo et al., 2012; Roep
et al., 2012; Sakaguchi et al., 2012; Steinman et al., 2012; Wek-
erle et al., 2012). In organ-specific autoimmune responses, T and
B lymphocytes – together with activated stromal lymphoid tis-
sue organizer cells – organize themselves as Tertiary lymphoid
organs (TLOs) adjacent to or even within the inflamed target
tissue (Moyron-Quiroz et al., 2004). Under these conditions, local-
ized chronic inflammation prompts TLO neogenesis and vice versa
TLOs amplify tissue inflammation. TLOs can therefore be viewed
as hallmarks of organ-specific autoimmunity and – possibly –
atherosclerosis (Figure 1). The immune system utilizes diverse
strategies to detect and pick up particulate or soluble antigens.
DCs constantly patrol peripheral tissues as sentinels to track down
antigen-derived danger signals to carry antigen to secondary lym-
phoid organs (SLOs) to initiate T cell responses (Steinman, 2012)
while follicular dendritic cell (FDCs) bind soluble antigens as
immune complexes to initiate and organize B cell affinity matura-
tion. What, then, may be the advantage of TLO neogenesis within
the target organ of autoimmunity versus antigen presentation in
SLOs? First, in TLOs, autoantigen can be presented within close
distance of its generation avoiding dilution thereby lowering the
antigen threshold to trigger an adaptive T cell response. Second,
the cytokine environment of TLOs may also stimulate recruitment
of blood monocytes and generate fully effective monocyte-derived
DCs (mDCs) in addition to conventional dendritic cells (cDCs;
Lee et al., 2007; Randolph et al., 2008a,b; Cheong et al., 2010; Choi
et al., 2011). Third, immune complexes with unprocessed antigen
can gain access to TLOs where they bind to FDCs within germi-
nal centers (GCs) at higher concentrations compared to FDCs in
the more distant SLOs (Kratz et al., 1996; Mackay and Brown-
ing, 1998; Stott et al., 1998; Kim et al., 1999; Luther et al., 2000;
Weyand et al., 2001; Itano and Jenkins, 2003; Kosco-Vilbois, 2003;
Moyron-Quiroz et al., 2004; Allen et al., 2007; Lee et al., 2007;
Timmer et al., 2007; Lund and Randall, 2010; Sweet et al., 2011).
Permissive conditions for SLO and TLO formation arise in the con-
nective tissues when lymphoid tissue organizer cells interact with
immune cells termed lymphoid tissue inducer cells (Roozendaal
and Mebius, 2011). This occurs during embryogenesis at predeter-
mined sites to generate lymph nodes and gut-associated lymphoid
tissues or at diverse locations in adult organisms to initiate the for-
mation of TLOs (Cupedo et al., 2004). Thus, unlike SLOs, TLOs
function as effective and, depending on the conditions, transient
organizers of adaptive immune responses in chronically inflamed
tissues. Why has it not be possible to clearly define functional
impacts of TLOs in any autoimmune disease? There is ample
evidence that breakdown of tolerance is required to convert clini-
cally silent autoimmune reactivity to autoimmune disease and this
breakdown of tolerance may not occur during TLO formation
per se (see below Figure 2). Importantly, breakdown of toler-
ance primarily occurs in the periphery in tissue microdomains
(Shlomchik et al., 2001; Shlomchik, 2008, 2009; Good-Jacobson
and Shlomchik, 2010).
Under conditions of tolerance breakdown, identification of the
triggers of lymphocyte activation, their emigration from SLOs
or TLOs, and mechanisms of lymphocyte homing to attack the
antigen-specific targets in human disease remain important issues
of autoimmune disease research including atherosclerosis (Hans-
son et al., 1989; Lang et al., 2005; Galkina and Ley, 2009; Her-
mansson et al., 2010; Hansson and Lundberg, 2011). Indeed,
TLOs are closely associated with various autoimmune diseases
but their presence does not seem to be sufficient to trigger organ
injury. To understand autoimmune-triggered organ dysfunction,
it is crucial to strictly distinguish autoimmune reactivity from
autoimmune disease. A major function of TLOs is to organize B
cell immunity: B cells reside, act, proliferate, and undergo affin-
ity maturation locally using the inflammatory survival niches and
lymphorganogenic chemokines such as CXCL13, CCL21, and lym-
photoxin (Schroder et al., 1996; Luster, 1998; Stott et al., 1998;
Kim et al., 1999; Gräbner et al., 2009; Sweet et al., 2011). Thus,
the initiation of autoimmune disease is the result of a multi-
step process in which TLO neogenesis appears to be required
but is not sufficient: Additional events including toll-like recep-
tor activation and breakdown of tissue barriers such as the blood
brain barrier in multiple sclerosis (see below) are needed to trig-
ger overt autoimmune disease (Cole et al., 2011; Hansson and
Lundberg, 2011). To facilitate local adaptive immune responses,
TLOs generate and assemble conduits, HEVs, and lymph ves-
sels to boost T and B cell recruitment and to promote their
movement within T cell areas or B cell follicles as shown for
ATLOs. These structures enhance the probability for TCR- or
BCR-carrying lymphocytes to find their cognate antigen close to
its generation. In ATLOs, we observed that HEV neogenesis and
maintenance is dependent on ongoing lymphotoxin β receptor
(LTβR) signaling (Figure 1). However, TLOs differ markedly from
SLOs in structure, cellularity, and function in several important
aspects. Although there is evidence from human autoimmune dis-
eases indicating that TLOs mount specific T and B cell immune
responses toward self-antigens (Fütterer et al., 1998; Kim et al.,
1999; Ettinger et al., 2001; Gommerman and Browning, 2003;
Cupedo et al., 2004; Browning, 2006; Lee et al., 2006), major
issues of their formation and functional impact on disease pro-
gression remain to be explored: (i) How do innate immune
cells, i.e., activated monocytes/macrophages, neutrophils, mast
cells, DCs, and lymphoid tissue inducer cells prompt adaptive
immune responses within the target tissue (Tellides et al., 2000;
Lopez-Diego and Weiner, 2008)? (ii) Does the formation of TLOs
require the presence of an antigen/autoantigen or is autoimmu-
nity a late event after TLOs have formed (Kosco-Vilbois, 2003;
Thaunat et al., 2005; Allen et al., 2007)? (iii) How does overt
autoimmune disease arise from clinically quiescent autoimmune
reactivity (Lang et al., 2005? (iv) Are immune responses in TLOs
and SLOs distinct (Farez et al., 2009)? (v) What is the relative
share of autoreactive T and B cells versus innate immune cells to
direct tissue destruction? (vi) How is the apparent equilibrium
between effector and tolerogenic arms of the immune system
in TLOs maintained under steady state conditions and how is
it disturbed during disease progression and/or disease relapse
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FIGURE 1 | ArteryTLOs arise in the aorta adventitia of agedApoE−/−
mice adjacent to atherosclerotic plaques. Cellularity, structures, and
territoriality within the diseased arterial wall indicate that ATLOs organize
inflammation-driven innate and adaptive immune responses in
atherosclerosis: TLO conduits allow the creation of chemokine and cytokine
gradients and the directed movement of T cells and DCs in lymph nodes (LNs)
and spleen (Cyster, 2003; Nolte et al., 2003; Sixt et al., 2005; Bajenoff et al.,
2006) and – by analogy – may maintain such gradients in the adventitia of
diseased artery segments in ATLOs. ATLO conduits connect the external
lamina of the arterial wall with HEVs in T cell areas and transport small MW
molecules. In unpublished analyses, we observed a dense network of nerve
axons within ATLOs but their impact remains unclear. Extensive newly
formed blood vessels provide nutrient and oxygen supply. ATLOs strongly
support T cell recruitment and recirculation whereas aberrant
lymphangiogenesis may promote recruitments of DCs and other immune
cells into the inflamed adventitia. ATLOs harbor several APCs including FDCs,
cDCs, mDCs, and B cells. Several B-2 cells at different stages of
differentiation and plasma cells are present in activated B cell follicles and the
ATLO periphery, respectively. We also identified increased populations of
innate B-1a and B-1b cells by FACS. Modified from Gräbner et al. (2009).
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FIGURE 2 |The balance of ATLO antigen-specific immune cell effectors
and their suppressor counterparts may be disturbed during
development of unstable atherosclerotic plaques. During long-lasting
transmural arterial wall inflammation autoantigens may be generated within
the diseased arterial wall and be presented by ATLO DCs (Steinman, 2012)
and FDCs (Good-Jacobson and Shlomchik, 2010; Reizis et al., 2011a,b). This
triggers generation of antigen-specific T and B cell effectors and their
regulatory counterparts (Fontenot and Rudensky, 2005; Gräbner et al.,
2009; Lund and Randall, 2010; Hu et al., unpublished) resulting in
atherosclerosis-specific – yet clinically silent – autoimmune reactivity under
steady state conditions. However, as ATLOs may organize the generation of
pools of memory T and B lymphocyte subsets, a subsequent disturbance of
the balance between autoreactive effectors and suppressors may
hyperactivate the pro-atherogenic lymphocyte subsets and concomitantly
compromise activity of their suppressors. Although mechanisms of
unstable plaque formation are poorly understood in atherosclerosis,
mechanisms of autoimmune injury of brain and other organs are better
understood. By analogy, autoimmune T cells may contribute to the
formation of vulnerable/unstable plaques during clinically significant
atherosclerosis. Definition of molecular mechanisms of the emergence of
autoreactivity from inflammation and the conversion of autoreactivity to
autoimmune disease in atherosclerosis and other bona fide autoimmune
diseases has a major potential to identify therapeutic targets. Note that
innate immune cells and their dichotomic subtypes including innate
B1-a/B1-b cells, natural T regulatory cells, and macrophage subtypes are not
depicted in this scenario but aspects of their functional impact are subject
to reviews in this series. Additional cell/cell interactions and marker
expression of effectors or suppressors are not shown for ease of reading.
(Kosco-Vilbois, 2003; Hansson, 2005;Ait-Oufella et al., 2006, 2010;
Herlands et al., 2008)? Answers to these questions will be crucial to
develop immune-based therapies to treat autoimmune disorders
and atherosclerosis. In this review, we focus on atherosclerosis-
and hyperlipidemia-dependent ATLO neogenesis in aged ApoE−/−
mice (Figure 1).
THE DEMANDING TASK TO DISTINGUISH CHRONIC
INFLAMMATION, ADAPTIVE IMMUNE RESPONSES,
AUTOIMMUNE REACTIVITY, AND AUTOIMMUNE DISEASE IN
ATHEROSCLEROSIS
Only few human autoimmune diseases, i.e., Hashimoto’s thyroidi-
tis, Grave’s disease, and myasthenia gravis, meet the direct Witebsky
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postulates of autoimmune diseases (Witebsky et al., 1957): Iso-
lation of a pathogenic autoantigen, isolation of a B cell clone
with exquisite specificity for autoantigen, demonstration that B cell
clones produce pathogenic autoantibodies in experimental trans-
fer experiments, T cells responding to pathogenic autoantigen in
an autologous mixed lymphocyte reaction, isolation of T cells
carrying a TCR with specificity for autoantigens, and cloning of
pathogenic T cells able to transfer autoimmune disease to another
individual (Olsson et al., 1990; Rose and Bona, 1993; McLach-
lan and Rapoport, 2004; Rose, 2006). In these classical organ-
specific autoimmune diseases, pathogenic autoantibodies against
thyroglobulin, thyroperoxidase, or nicotinic acetylcholine recep-
tors have been demonstrated to trigger the disease (Ettinger et al.,
2001; Carragher et al., 2008). For most clinically important human
autoimmune diseases, i.e., rheumatoid arthritis, diabetes melli-
tus type I, and multiple sclerosis, however, Witebsky postulates
are not completely met and evidence for autoimmune-triggered
organ damage is strong yet circumstantial. Moreover, much of
the evidence that chronic inflammatory human diseases are asso-
ciated with a significant autoimmune component comes from
animal models (Olsson et al., 1990; Ettinger et al., 2001; McLach-
lan and Rapoport, 2004; Lee et al., 2006; Zhou et al., 2006; Timmer
et al., 2007; Coppieters et al., 2012). Interestingly, the American
Autoimmune Related Diseases Association does not list athero-
sclerosis as an autoimmune or an autoimmune related disease
(http://www.aarda.org). The view that atherosclerosis is associated
with autoimmune responses, a view that we favor (Grundtmann
et al., 2011), is largely derived from circumstantial evidence such
as the presence of autoantibodies directed against presumptive
autoantigens such as heat shock protein 60 or oxidized LDL (Van
Puijvelde et al., 2007), and more recently by the demonstration that
DC-like cells are present in atherosclerotic plaques (Wick et al.,
1997, 2004; Lusis, 2000; Glass and Witztum, 2001; Libby, 2002;
Witztum, 2002; Hansson, 2005; Tedgui and Mallat, 2006; Steinberg
and Witztum, 2010; Choi et al., 2011; Libby et al., 2011; Weber and
Noels,2011). However,autoreactive T and B cells and autoantibod-
ies can be detected in a large percentage of the healthy population
and their presence often does not correlate with clinically signif-
icant autoimmune diseases. Therefore, when compared to well
characterized human autoimmune disorders, our understanding
of autoimmunity in atherosclerosis is at an early stage. Further-
more, unlike multiple sclerosis (Lopez-Diego and Weiner, 2008),
diabetes mellitus type I (Lee et al., 2006), and rheumatoid arthritis
(Aloisi and Pujol-Borrell, 2006), in which immune-based thera-
pies have entered routine clinical practice, similar therapies for
atherosclerosis are not in sight. Why is progress into the autoim-
mune origin of atherosclerosis lagging behind? One reason may be
that it has been an extremely challenging task to isolate pathogenic
autoantibodies for most human diseases including atherosclerosis
because chronic inflammation is associated with the generation
of multiple autoantigens, a phenomenon referred to as epitope
spreading (Miller et al., 1997; McMahon et al., 2005). This makes
identification of disease-causing as opposed to irrelevant bystander
autoantigens a complex task. It has also been difficult to under-
stand the mechanisms underlying the clinical courses of chronic
inflammatory diseases such as relapses, long periods of intermit-
tent latency periods, and periods of violent progressive phases.
Unfortunately, mouse models rarely mimic these events. However,
the existence of polyclonal T cell and antibody responses that may
initiate a vicious circle of immune injury and inflammation is sup-
ported by a large body of circumstantial evidence in many of these
diseases including atherosclerosis (Olsson et al., 1990; Ettinger
et al., 2001; McLachlan and Rapoport, 2004; Browning, 2006; Lee
et al., 2006; Herlands et al., 2008; Gräbner et al., 2009; Good-
Jacobson and Shlomchik, 2010; Coppieters et al., 2012; Kuchroo
et al., 2012; Roep et al., 2012). Dramatic antigen spreading during
the primary progressive and relapsing-remitting phases of multi-
ple sclerosis exemplifies the daunting challenges to identify culprit
autoantigens in atherosclerosis (Quintana et al., 2008,2012). Other
reasons for the slow progress into autoimmunity of atherosclero-
sis are its multistep pathogenesis, the strong association with age
(the major but least understood risk factor for atherosclerosis,
see below), its complex risk factor profile, the crucial influence of
environmental factors on its progression, and the lack of a robust
mouse model. TLOs and ATLOs share functional and structural
features with SLOs including separate T cell areas and B cell folli-
cles yet important differences are apparent. Although the wild-type
mouse adventitia contains a network of lymph vessels, the newly
formed ATLO lymph vessels show aberrant features. Their dis-
tended lumen is congested with a large number of leukocytes
whose movement and/or impaired transendothelial migration
is reminiscent of tumor lymphangiogenesis (Oliver, 2004; Fur-
tado et al., 2007; Gräbner et al., 2009). It will be of interest to
determine the mechanisms and functional implications of these
abnormalities and analyze which type of immune cells migrate
through the aberrant ATLO lymph vessels. Recently, we analyzed
the phenotypes of immune cells by immunofluorescence and flow
cytometry. ATLOs contain large numbers of plasma cells which are
rare in LNs or spleen. The origin of these plasma cells in diseased
arteries is not known but in analogy to rheumatoid arthritis they
may derive from activated B cell follicles (Kim et al., 1999). A major
question regarding the organization of the B cell adaptive immune
response is the role of FDCs in the B cell follicles. It has been shown
that FDCs and affinity maturation of B cells require ongoing
LTβR signaling as well as the presence of antigen (Schroder et al.,
1996; Fütterer et al., 1998; Mackay and Browning, 1998; Endres
et al., 1999; Gommerman and Browning, 2003; Kosco-Vilbois,
2003; Victoratos et al., 2006). These data raise the important
possibility that ATLO FDCs present arterial wall-derived autoanti-
gens and that B-2 cells undergo affinity maturation giving rise
to memory and/or plasma cells. Moreover, we recently observed
that ATLOs contain significant numbers of B-1 cells that pre-
dominantly belong to the B-1b cell subtype (Srikakulapu et al.,
unpublished observations). These data indicate that ATLOs not
only promote T cell-dependent immune responses but also T cell-
independent humoral immune responses that are carried out by
natural antibody-producing B-1 cells within the diseased arterial
wall. To understand the immune responses in ATLOs better we
have used laser capture microdissection-based microarray analy-
ses of ATLOs and compared transcriptomes of ATLOs directly with
those of the draining renal LNs (Beer et al., 2011; Hu et al., unpub-
lished data). When ATLOs were compared with the adventitia of
wild-type aorta large numbers of immune response-regulating
genes were acquired. These ATLO transcriptomes resembled those
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of SLOs, yet inflammation-regulating genes were expressed at
significantly higher levels in ATLOs compared to LNs. Though
characterization of macrophage subtypes in atherosclerosis has
progressed during recent years. ATLO macrophage subtypes have
not yet been characterized in detail.
SEARCH FOR A MOUSE MODEL OF ATHEROSCLEROSIS
AUTOIMMUNE RESPONSES
As there are severe restrictions to study mechanisms of autoim-
mune diseases in humans, mouse models have been essential to
understand their basis, complexity, and multistep features (Good-
now, 2007; Kuchroo et al., 2012; Roep et al., 2012). While each
of the mouse models has its own limitations, there is a need to
develop new models and experimental criteria in which distinct
aspects of autoimmunity and the triggers of tolerance breakdown
can be addressed (Wekerle et al., 2012). The well established mouse
models experimental autoimmune encephalomyelitis (EAE) and
collagen-induced arthritis (CIA) have guided the implementation
of current therapeutic strategies in the clinic and some have even
entered routine clinical practice (Lopez-Diego and Weiner, 2008;
McInnes and Schett, 2011; Blumberg et al., 2012; Kuchroo et al.,
2012). These examples show the enormous importance of suitable
mouse models for autoimmune disease research. Although several
attempts have been reported to address aspects of atherosclerosis
autoimmunity in mice, it is our view that there is currently no
robust mouse model to faithfully examine atherosclerosis autoim-
mune responses (Rosenfeld et al., 2000; Grundtmann et al., 2011;
Libby et al., 2011). In this context, it is informative to briefly review
the structure and cellularity of atherosclerotic plaques in humans
in comparison to mouse models. Human atherosclerosis is clin-
ically silent for long periods of time. It is now established that
plaque growth is necessary but not sufficient to cause disease.
An increase in plaque size is compensated by extensive outward
media remodeling preventing tissue infarcts during early athero-
sclerosis. Observational studies of human coronary artery disease
across all age groups show that asymptomatic fibroatheromatous
plaque buildup can continue for decades without developing into
clinically overt disease (Rekhter, 2002; Virmani et al., 2005). Ini-
tiation of disease requires development of vulnerable plaques as
evidenced by fibrous cap thinning, enlargement of the necrotic
core, macrophage activation, plaque neoangiogenesis, plaque rup-
ture, bleeding, and thrombosis. However, the mechanisms how
stable plaques undergo prototypical alterations to become vulner-
able plaques are not well understood (Virmani et al., 2005) but
autoimmune T cells have been held responsible (Hansson, 2005).
In contrast to human disease, early inflammatory cell infiltrates of
mouse atherosclerotic plaques consist of cDCs, mDCs, M1- and
M2-type macrophages, CD4+ and CD8+ T cells, and proliferating
smooth muscle cells covered by a stable fibrous cap. In the majority
of reports, adolescent mice as young as 5–9 weeks are maintained
on atherogenic Western-type diets for comparably short periods
of time. Despite severe atherosclerosis, compensatory arterial wall
remodeling ensures blood flow and even severely diseased mouse
coronary arteries are never associated with tissue infarcts, even in
aged ApoE−/− mice (Gräbner et al. unpublished; see below). The
disease readout is often the size of the plaque relative to the size
of the media, i.e., the intima/media ratio and/or the area covered
by macrophages/foam cells. While determination of intima/media
ratios is useful to examine plaque growth it may not be very helpful
to examine clinically significant disease. It is therefore possible that
if autoimmune responses are to be identified in atherosclerosis,
the value of current mouse models appears to be limited. How-
ever, some features of vulnerable plaques and myocardial infarcts
have been induced in ApoE−/− mice under distinct experimen-
tal conditions (Caligiuri et al., 1999). For instance, supplementing
the Western diet with cholate induces vulnerable-like plaques but
it also causes systemic inflammatory disease and organ damage
of liver, skin, kidney, and myocardium. One important parame-
ter seems to be age which has been shown to generate several but
not all parameters of vulnerable plaques in the innominate artery
of ApoE−/− mice (Rosenfeld et al., 2000; Roncal et al., 2010).
We observed that the infiltrate of early atherosclerotic plaques
in the aorta is replaced by an increasing share of extracellular
matrix and extensive outward media remodeling during aging of
ApoE−/− mice. Although the media is infiltrated by plaque leuko-
cytes, vulnerable plaques – i.e., plaque rupture, thrombosis, and
myocardial infarction – cannot be observed even in mice as old
as 120 weeks. Thus, young mice though useful to delineate aspects
of plaque growth and adaptive T cell immune responses (Cheong
et al., 2010; Choi et al., 2011; Hansson and Hermansson, 2011)
may be less suitable to examine clinical disease or autoimmune
responses.
ATLOs EMERGE IN THE ADVENTITIA IN RESPONSE TO
PLAQUE INFLAMMATION IN AGED ApoE−/− MICE AND
INDICATE ROBUST AUTOIMMUNE T AND B CELL
RESPONSES
As discussed above, atherosclerosis complies with indirect and cir-
cumstantial lines of evidence that support a role of autoimmunity
in this disease. These include disease-suppressing effects of natural
antibodies, oligoclonal T cell expansion toward potential autoanti-
gens, protective roles of Tregs, pro-, and anti-atherogenic impacts
of distinct B cell subtypes, and inhibition of plaque growth by vac-
cination (Mach et al., 1998; Ludewig et al., 2000; Zhou et al., 2000;
Glass and Witztum, 2001; Caligiuri et al., 2002; Major et al., 2002;
Witztum, 2002; Binder et al., 2003, 2005; Schiopu et al., 2004; Ait-
Oufella et al., 2006; Tedgui and Mallat, 2006; Michel et al., 2007;
Randolph et al., 2008a,b; Packard et al., 2009; Geissmann et al.,
2010a,b; Hermansson et al., 2010; Steinberg and Witztum, 2010;
Libby et al., 2011; Manthey and Zernecke, 2011; Weber and Noels,
2011). However, major issues of atherosclerosis immune responses
and autoimmunity remain unresolved: (i) Where are adaptive and
autoimmune responses organized? (ii) Which immune cells par-
ticipate in arterial wall remodeling during different stages of the
disease? (iii) Is the adaptive immune response in atherosclerosis
systemic or organ-specific? (iv) Are there periods of heightened
immune activation and what are the triggers of relapses and violent
immune cell activities in acute coronary syndromes? (v) What are
the contributions of innate immunity carried out by subtypes of
blood-derived monocyte/macrophages and foam cells, of DC sub-
types, and of B-1 cells? (vi) Are there antigen-specific CD4+ and/or
CD8+ effector T cells directly targeting structures of the arterial
wall? (vii) What causes dysfunction of the balance between effector
cells and tolerogenic DCs, Tregs, and Bregs? And, most importantly
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(viii) what is the nature of the disease-triggering autoantigen(s)? It
has been widely assumed that T cell responses are organized either
in atherosclerotic plaques or in SLOs (Lusis, 2000; Libby, 2002;
Witztum, 2002; Wick et al., 2004; Tedgui and Mallat, 2006; Grundt-
mann et al., 2011; Hansson and Hermansson, 2011). Until recently,
the leukocyte infiltrates in the adventitia during atherogenesis have
not been characterized in detail and adventitial inflammation has
largely been regarded as an epiphenomenon with little relevance
to disease progression although the role of adventitial vasa vasora
has received some attention (Virmani et al., 2005). Importantly,
the accumulation of leukocytes in the adventitia during atheroge-
nesis has been noted decades ago. Small round cell infiltrates were
reported in the adventitia of patients afflicted with coronary artery
disease. The adventitia has been the subject of original reports and
its potential role in atherogenesis has been reviewed (Gerlis, 1956;
Schwartz and Mitchell, 1962; Stefanadis et al., 1995; Scott et al.,
1996; Walton et al., 1997; Kwon et al., 1998; Labinaz et al., 1999;
Pels et al., 1999; Herrmann et al., 2001; Houtkamp et al., 2001;
Okamoto et al., 2001; Zhao et al., 2004; Moos et al., 2005; Cheema
et al., 2006; Galkina et al., 2006; Michel et al., 2007; Watanabe et al.,
2007). Local humoral immune responses have been suggested to
be organized by atherosclerosis-associated adventitial lymphoid
aggregates containing B cells and FDCs (Houtkamp et al., 2001).
The detailed characterization of ATLO T and B cells and of the
ATLO microarchitecture provides strong evidence for an autoim-
mune contribution during late stage atherosclerosis: ATLOs show
striking similarities to TLOs in prototypic organ-specific autoim-
mune disorders including immune cell subtypes, distinct struc-
tures such as HEVs, and a high degree of territoriality adjacent
to the target organ (for atherosclerosis adjacent to atherosclerotic
plaques; Moos et al., 2005; Galkina et al., 2006; Galkina and Ley,
2009; Gräbner et al., 2009). Our studies in ApoE−/− mice during
aging revealed that adventitial T cell infiltrates occur in parallel
with the formation of intima plaques in the innominate artery and
in the abdominal aorta, generating large immune cell aggregates
after the age of 52 weeks. ATLOs are now among the best char-
acterized TLOs in any chronic inflammatory disease. Remarkably,
the number of T cells in the adventitia of diseased aorta segments
exceeds the number of plaque T cells by a factor of>80-fold (Moos
et al., 2005). Subsequently, B cell aggregates form and DCs as well
as plasma cells localize in the ATLO periphery (Zhao et al., 2004;
Moos et al., 2005; Gräbner et al., 2009). Thus, while early ath-
erosclerosis is associated with significant T cell infiltrates in the
intima, T cell density in plaques decreases over time whereas it dra-
matically increases in the adventitia during aging. Furthermore, B
cells, which are absent in the normal aorta and in atherosclerotic
plaques, form aggregates during intermediate stages of ATLO neo-
genesis, whereas advanced stages of ATLOs are characterized by
large B cell follicles and ectopic GCs containing FDC networks
with proliferating B cells (Figure 1). Importantly, FDCs indicate
adaptive B cell responses, antigen-specific B memory cell forma-
tion, and affinity maturation of B cells. The presence of FDCs in
ATLOs and of proliferating B cells in ATLO GCs provide strong evi-
dence for a robust antigen-specific autoimmune response within
the diseased arterial wall adventitia (Figure 2). Delineation of
ATLO cellularity suggests that the diseased artery is capable of
organizing both T cell and B cell autoimmune responses and that
these responses are not observed in young animals. In ApoE−/−
mice, we observed preferential formation of ATLOs in the upper
portion of the abdominal aorta but occasionally also in coronary
and pulmonary arteries, in the adventitia of the brachiocephalic
trunk, in the adventitia of the innominate artery, in aortic valves,
and rarely in the myocardium. Apparently, the connective tissue
of the adventitia of the abdominal aorta provides particularly per-
missive conditions for ATLO formation but the molecular basis
for this preferred location is not known. We never observed ATLO
neogenesis in artery segments that are not burdened by advanced
atherosclerotic plaques in the intima nor did we observe ATLOs in
the intima. However, the formation of large and advanced plaques
is not sufficient to trigger ATLO formation as atherosclerosis in
ApoE−/− mice begins and is most advanced in the aortic arch
where ATLOs can only rarely be observed. The occurrence of
ATLOs in the abdominal aorta adventitia is reminiscent of TLO
formation in the meninges in multiple sclerosis. TLO formation
requires long-lasting interactions between immune cells and lym-
phoid tissue organizer cells in multiple feedback loops involving
a series of hematopoietic and connective-tissue-derived cytokines
(Zinkernagel et al., 1997; Mackay and Browning,1998; Luther et al.,
2000; Weyand et al., 2001; Mebius, 2003; Cupedo and Mebius,
2005; Ware, 2005; Timmer et al., 2007; Van De Pavert et al., 2009;
Roozendaal and Mebius, 2011). In atherosclerosis, lymphoid tissue
organizer cells may arise from media smooth muscle cells as indi-
cated by in vitro studies. Interestingly, smooth muscle cells, but not
endothelial cells, stimulated in vitro with agonistic anti-LTβR anti-
bodies acquire features of lymphoid tissue organizer cells including
induction of the lymphorganogenic chemokine CXCL13 (Lötzer
et al., 2010). Alternatively, myofibroblasts in the adventitia of large
arteries during atherogenesis may act as lymphoid tissue orga-
nizer cells to support ATLO formation. A more detailed knowledge
about development and function of ATLOs will likely help to better
understand both innate and adaptive atherosclerosis immunity.
THE TERRITORIALITY OF ATHEROSCLEROSIS IMMUNE
RESPONSES: PLAQUE AND/OR ADVENTITIA,
ORGAN-SPECIFIC, AND/OR SYSTEMIC?
Since the‘response to injury hypothesis’proposed four decades ago
emphasized the role of smooth muscle cells for atherosclerosis pro-
gression (Ross and Glomset, 1973, 1976a,b), it is now established
that adaptive immune responses contribute to disease progression.
The majority of investigators assume that these responses are car-
ried out in the intima of the diseased arterial wall and/or in SLOs
(Wick et al., 1997, 2004; Lusis, 2000; Zhou et al., 2000; Libby, 2002;
Witztum, 2002; Tedgui and Mallat, 2006; Hansson and Hermans-
son, 2011; Weber and Noels, 2011). Immune response-regulating
cells in atherosclerosis in plaques have also been termed vascular-
associated lymphoid tissue (Wick et al., 1997, 2004; Grundtmann
et al., 2011) and it has been proposed that epitopes of heat shock
protein Hsp60 or oxLDL or LDL are the culprit autoantigens
(Paulsson et al., 2000; Schiopu et al., 2004; Randolph et al., 2008a,b;
Packard et al., 2009; Hermansson et al., 2010; Klingenberg et al.,
2010; Steinberg and Witztum, 2010; Manthey and Zernecke, 2011).
Several immune cells are systemically altered by hyperlipidemia in
mouse models (Swirski et al., 2007; Tacke et al., 2007). Under
conditions of acute myocardial infarction, spleen monocytes are
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rapidly mobilized into the heart (Leuschner et al., 2012). How-
ever, it is much less clear whether there are systemic alterations in
the number, activation, or lymphocyte subset composition during
atherogenesis in hyperlipidemic mice maintained under normal
mouse chow. Thus, despite extensive efforts it is still largely unclear
whether atherosclerosis is associated with organ-specific or sys-
temic adaptive and/or autoimmune reactions. Systemic vaccina-
tion approaches using various presumptive autoantigens includ-
ing LDL, oxLDL, and heat shock protein in hyperlipidemic mice
resulted in attenuation or acceleration of disease severity providing
circumstantial evidence for systemic immune activity. Moreover,
T cell-oriented intervention in mice vaccinated with oxLDL also
led to a decrease in atherosclerosis severity but the mice generated
a marked T cell response against LDL rather than oxLDL epitopes
(Hermansson et al., 2010; Klingenberg et al., 2010). Depletion
of T regulatory cells using anti-CD25 antibodies in hyperlipi-
demic mice increased atherosclerosis pathology and anti-CD20
antibody-induced B cell depletion also resulted in a decrease in
disease severity implicating anti-atherogenic actions of natural T
regulatory (nTregs) and pro-atherogenic actions of B cell subsets
(Ait-Oufella et al., 2006, 2010). All these observations provide cir-
cumstantial evidence that T and B cell responses affect atheroscle-
rosis systemically and dichotomically. A number of recent studies
including our own are more consistent with the view, however,
that atherosclerosis is an organ-specific disease. This suggestion is
based on the cellular composition and structure of ATLOs in the
adventitia of ApoE−/−mice (Figures 1 and 2). In addition, age has
been associated with some autoimmune diseases (Weyand et al.,
2001; Goronzy and Weyand, 2003; Linton and Dorshkind, 2004;
Wick et al., 2004; Lindström and Robinson, 2010) and age is the
most important though least understood risk factor for atheroscle-
rosis. As we observed a large increase in adventitial immune cell
accumulation in aged ApoE−/− mice, the possibility that immune
senescence contributes to atherosclerosis deserves attention (Lin-
ton and Dorshkind, 2004). The first initial stages of ATLOs were
noted at around 52 weeks of age with preferential formation in
the upper abdominal aorta where aortic aneurysms are formed
(Zhao et al., 2004). Fully developed ATLOs including activated
GCs and FDCs emerged between 52 and 78 weeks of age in aorta
segments burdened with atherosclerotic plaques. Atherosclerosis
becomes clinically significant only when the late stages are reached,
often after short periods of violent progression of plaque growth,
leading eventually to plaque instability and rupture (see above).
Unfortunately, such stages are difficult to study in mouse models
as hyperlipidemic mice have a normal lifespan and never develop
myocardial infarction under steady state conditions and normal
mouse chow, indicating that poorly understood secondary events
are required to initiate clinically severe disease (Figure 2). For
example, it is not known whether immune senescence is involved
and to which extent aging of stromal cells such as media smooth
muscle cells participates in atherosclerosis progression (Lindström
and Robinson, 2010; Roozendaal and Mebius, 2011).
AUTOIMMUNE REACTIVITY IS NOT SUFFICIENT TO INITIATE
AUTOIMMUNE DISEASE
Several caveats merit consideration regarding a pathogenic role
of ATLOs in atherosclerosis. First, TLOs as organizers of adaptive
immune responses generate both effector lymphocytes and con-
comitantly their immunosuppressive counterparts in an apparent
equilibrium (Figure 2). It is therefore not clear whether, when,
and how the balance between effector and tolerogenic lympho-
cytes is disturbed to cause autoimmune tissue injury. Second, the
relative contribution of inflammation and specific lymphocyte
responses to tissue injury have not yet been defined. It is pos-
sible that silent disease phases are characterized by a well-tuned
balance between effector and suppressor activities and that dis-
ease relapses and rapid progression are caused by activation of
effector lymphocytes and/or inhibition of suppressor activities.
The important question what triggers this lymphocyte activation
still has to be answered but molecular mimicry, i.e., crossreactivity
between bacterial or viral epitopes with epitopes of self-antigens,
merits attention (Olson et al., 2001; Binder et al., 2003). A large
body of evidence supports the assumption that atherosclerosis
involves T and B cell immune responses that promote or inhibit
plaque growth (Ramshaw and Parums, 1990;Wick et al., 1997,
2004; Mach et al., 1998; Paulsson et al., 2000; Zhou et al., 2000;
Weyand et al., 2001; Major et al., 2002; Schiopu et al., 2004; Zhao
et al., 2004; Moos et al., 2005;Ait-Oufella et al., 2006, 2010; Galk-
ina et al., 2006; Niessner et al., 2006; Van Puijvelde et al., 2007;
Hermansson et al., 2010; Kyaw et al., 2010; Steinberg and Witz-
tum, 2010; Grundtmann et al., 2011). The dichotomic nature of
organ-specific autoimmune diseases is well established for EAE
as shown by the various immune cell subsets in meningeal TLOs
(Aloisi and Pujol-Borrell, 2006). The presence of discrete T cell
areas and FDC networks within activated GCs of ATLOs provides
the first indirect evidence that the transmural inflammation of
the arterial wall generates atherosclerosis-specific antigen(s) that
may trigger specific T cell and B cell immune responses. Similar to
SLOs, organization of the ATLO immune response is dependent
on the LTβR (Alimzhanov et al., 1997; Endres et al., 1999; Kosco-
Vilbois, 2003; Weih and Caamano, 2003; Oliver, 2004; Ware, 2005;
Victoratos et al., 2006; Allen et al., 2007; Furtado et al., 2007; Lee
et al., 2007; Gräbner et al., 2009). Importantly, lymphotoxin sig-
naling through the LTβR is not only essential for the maintenance
of FDC networks and for immunoglobulin affinity maturation
(Fütterer et al., 1998; Gommerman and Browning, 2003), but it
also regulates autoimmune disease in a mouse model of diabetes
mellitus type I (Ettinger et al., 2001; Lee et al., 2006). We specu-
late that ATLOs contain pro-atherogenic and anti-atherogenic T
cells as well as B cells in apparent equilibria, raising the impor-
tant question how this balance might be disturbed during disease
progression (Figures 1 and 2). The complexity of the immune
response in atherosclerosis precludes for now to predict what these
mechanisms may be. For instance, the tolerogenic arms of the ath-
erosclerosis adaptive immune response might be compromised. To
examine this possibility at a cellular level, further studies of arterial
wall Treg cells and of B-1 cells should be performed in addition
to cDCs which have recently been shown to exert a protective
role during early stages of atherosclerosis in young ApoE−/− mice
(Choi et al., 2011). Marked increase of local lymphocyte recircula-
tion, recruitment, functional conduit formation, blood vessel, and
HEV neogenesis as well as pathological lymphangiogenesis are all
indicative for autoimmune reactivity but not consequentially of
autoimmune disease or arterial wall injury. It is recognized that
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autoimmune diseases in humans develop in separable steps and
that only in the late stages, when tolerance against autoantigen(s)
is breaking down, conversion to explicit self-reactivity associated
with debilitating tissue destruction can be observed (Lang et al.,
2005). In the respective EAE and CIA mouse models for human
multiple sclerosis (TLOs form in the meninges) and rheumatoid
arthritis (TLOs form in the synovial membrane and bone adjacent
to the joint cartilage), the disease appears to go through phases of
relapses and attenuation and relapses are often triggered by infec-
tions and it has been suggested that toll-like receptor signaling may
be involved in disease progression (Leadbetter et al., 2002; Lang
et al., 2005; Herlands et al., 2008; Farez et al., 2009; Garin et al.,
2010).
CONCLUDING REMARKS
The autoimmune hypothesis of atherosclerosis is based on indi-
rect and circumstantial evidence. Much work is needed to obtain
more direct evidence for participation of autoreactive lympho-
cytes in the clinically important stages of the disease when stable
clinically silent atherosclerosis proceeds to vulnerable plaques.
ATLO immune cell phenotypes, formation of conduits, HEVs,
and aberrant lymph vessels indicate that hyperlipidemia-driven
atherosclerosis involves significant innate and adaptive autoim-
mune responses. Mouse and human ATLOs may provide new
experimental systems to isolate atherogenic autoantibodies and
atherogenic T and B cell effectors and their antigen-specific coun-
terparts carrying T and B cell receptors with specificity for epitopes
of arterial wall-derived autoantigen(s). Studies of adventitial tis-
sues could also facilitate identification of atherosclerosis-related
autoantigens. Moreover, ATLOs may provide a new experimen-
tal model to identify the mechanisms how overt autoimmune
atherosclerosis disease emerges from clinically silent autoimmune
reactivity. This will require a considerably improved understand-
ing of the functional impacts of adaptive immune cell sub-
sets that act on the arterial wall. Delineation of the mecha-
nisms underlying the disturbance of the equilibrium between
these subsets may provide clues for translational research into
human atherosclerosis and open avenues for immune-based
therapeutics.
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